Common Stock, par value $0.01 per share

OPKO HEALTH, INC.

4400 BISCAYNE BLVD., MIAMI, FL, 33137

Gamma Trust directly beneficially owns 213,751,448 shares of Common Stock. The 213,751,448 total shares of Common Stock beneficially owned by Gamma Trust constitute approximately 27.0% of the Issuer's outstanding shares of Common Stock, based upon 793,051,553 shares of Common Stock outstanding as of April 3, 2025 as communicated by the Issuer to the Reporting Person. Dr. Frost is the sole trustee of Gamma Trust and holds sole voting and dispositive power with respect to 213,751,448 shares of Common Stock. Frost Nevada directly beneficially owns 30,127,177 shares of Common Stock. The 30,127,177 total shares of Common Stock beneficially owned by Frost Nevada constitute approximately 3.8% of the Issuer's outstanding shares of Common Stock, based upon 793,051,553 shares of Common Stock outstanding as of April 3, 2025 as communicated by the Issuer to the Reporting Person. Dr. Frost is the sole trustee of Frost Nevada and holds sole voting and dispositive power with respect to 30,127,177 shares of Common Stock. Dr. Frost, as the sole trustee of Gamma Trust, may be deemed to beneficially own the 213,751,448 shares of Common Stock beneficially owned by Gamma Trust. Dr. Frost, as the sole trustee of Frost Nevada, may be deemed to beneficially own the 30,127,177 shares of Common Stock beneficially owned by Frost Nevada. In addition, the Phillip and Patricia Frost Philanthropic Foundation, Inc., which is controlled by Dr. Frost and his wife, owns 2,851,830 shares of Common Stock. Dr. Frost individually owns 3,068,951 shares of Common Stock and has stock options to acquire 2,600,000 shares of Common Stock, which are exercisable within 60 days of the date hereof, and has sole voting and dispositive power over each. The 252,399,406 shares of Common Stock beneficially owned by Dr. Frost constitute approximately 31.7% of the Issuer's outstanding shares of Common Stock, based upon (i) 793,051,553 shares of Common Stock outstanding as of April 3, 2025 as communicated by the Issuer to the Reporting Person; and (ii) options to acquire 2,600,000 shares of Common Stock, which are exercisable within 60 days of the date hereof. Dr. Frost, as sole trustee of Gamma Trust, has sole voting and dispositive power over 213,751,448 shares of Common Stock. Dr. Frost, as sole trustee of Frost Nevada, has sole voting and dispositive power over 30,127,177 shares of Common Stock. Dr. Frost has shared voting and dispositive power with respect to 2,851,830 shares of Common Stock owned by the Phillip and Patricia Frost Philanthropic Foundation, Inc. Dr. Frost's ownership position excludes restricted stock units that give him a contingent right to receive up to 500,000 shares of Common Stock, which will not begin to vest until July, 2026.

Gamma Trust directly beneficially owns 213,751,448 shares of Common Stock. The 213,751,448 total shares of Common Stock beneficially owned by Gamma Trust constitute approximately 27.0% of the Issuer's outstanding shares of Common Stock, based upon 793,051,553 shares of Common Stock outstanding as of April 3, 2025 as communicated by the Issuer to the Reporting Person. Dr. Frost is the sole trustee of Gamma Trust and holds sole voting and dispositive power with respect to 213,751,448 shares of Common Stock. Frost Nevada directly beneficially owns 30,127,177 shares of Common Stock. The 30,127,177 total shares of Common Stock beneficially owned by Frost Nevada constitute approximately 3.8% of the Issuer's outstanding shares of Common Stock, based upon 793,051,553 shares of Common Stock outstanding as of April 3, 2025 as communicated by the Issuer to the Reporting Person. Dr. Frost is the sole trustee of Frost Nevada and holds sole voting and dispositive power with respect to 30,127,177 shares of Common Stock. Dr. Frost, as the sole trustee of Gamma Trust, may be deemed to beneficially own the 213,751,448 shares of Common Stock beneficially owned by Gamma Trust. Dr. Frost, as the sole trustee of Frost Nevada, may be deemed to beneficially own the 30,127,177 shares of Common Stock beneficially owned by Frost Nevada. In addition, the Phillip and Patricia Frost Philanthropic Foundation, Inc., which is controlled by Dr. Frost and his wife, owns 2,851,830 shares of Common Stock. Dr. Frost individually owns 3,068,951 shares of Common Stock and has stock options to acquire 2,600,000 shares of Common Stock, which are exercisable within 60 days of the date hereof, and has sole voting and dispositive power over each. The 252,399,406 shares of Common Stock beneficially owned by Dr. Frost constitute approximately 31.7% of the Issuer's outstanding shares of Common Stock, based upon (i) 793,051,553 shares of Common Stock outstanding as of April 3, 2025 as communicated by the Issuer to the Reporting Person; and (ii) options to acquire 2,600,000 shares of Common Stock, which are exercisable within 60 days of the date hereof. Dr. Frost, as sole trustee of Gamma Trust, has sole voting and dispositive power over 213,751,448 shares of Common Stock. Dr. Frost, as sole trustee of Frost Nevada, has sole voting and dispositive power over 30,127,177 shares of Common Stock. Dr. Frost has shared voting and dispositive power with respect to 2,851,830 shares of Common Stock owned by the Phillip and Patricia Frost Philanthropic Foundation, Inc. Dr. Frost's ownership position excludes restricted stock units that give him a contingent right to receive up to 500,000 shares of Common Stock, which will not begin to vest until July, 2026.

In the last 60 days prior to the filing of this Amendment No. 26, Frost Nevada and Dr. Frost have not effected any transactions in the shares of Common Stock. In the last 60 days prior to the filing of this Amendment No. 26, Gamma Trust acquired a total of 517,434 shares of Common Stock on the open market at prices ranging from $1.645 to $1.745 per share for an aggregate purchase price of approximately $882,360.00, as set forth below: Date Shares of Common Stock Aggregate Purchase Price Weighted Average Price Per Share February 28, 2025 67,434 $ 115,312.14 $ 1.71 March 17, 2025 200,000 $ 347,813.39 $ 1.7391 March 28, 2025 150,000 $ 254,389.13 $ 1.6959 April 1, 2025 100,000 $ 164,845.35 $ 1.6485

Except as described herein, no other person is known by any Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them.